Each Collection Site is a modular pod structures that serves as a testing centre for QuestCap’s subsidiary, Collection Sites, LLC and their COVID-19 “Test Before You Go” locations across the United States.
The testing pods are licensed by CLIA registered Alcala Labs, and staffed by trained technicians offering both COVID-19 antigen and IgG/IgM antibody testing, with results in 24 hours.
Collection Site Economics
Test (US $):
Collection Site Potential Monthly Revenue (US $):
Test Before You Go
Speed and accuracy are vital for a comprehensive testing program. Rapid antigen testing can play a vital role. One needs to know do you have the virus. That is best determined by seeing if genetic material is present via PCR. These tests have a bottleneck and results are slow and the tests are expensive. The next information to know is can you detect any viral antigen. And finally what is important to know for each and every one of us is: Has your immune system fought back. This is most easily determined by antibody testing, which is fast, accurate, inexpensive, available in pop up stations and key to a full understanding of what is happening in your own body. The results also inform us of a community’s experience as a society as we live within a pandemic viral environment.
MD PROFESSOR OF NEUROLOGY, STANFORD
Learn More About QuestCap’s Quick and Convenient COVID-19 Testing Solution
COVID-19 Antigen SARS-CoV-2 Detection Test for rapid diagnosis of COVID-19, positive or negative results. Collection Sites, through its laboratory partner, Alcala Labs, is also performing COVID-19 IgG/IgM Rapid Test Cassette testing intended for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2. The test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Testing is limited to laboratories like Alcala Labs certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C 263a, to perform moderate or high complexity tests. Results are for the detection of SARS CoV-2 antibodies. IgM and IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.
Each Collection Site will have a regulatory certification necessary to perform COVID testing.
This certification is comprised of Alcala Labs’ CLIA certificate as a moderate and high complexity lab, notice to local health authorities of the testing, validations of the test accuracy, the FDA approvals or waivers for the tests being performed, and written clearance from the chief regulator overseeing laboratory testing at the California Department of Public Health.
Yes, each Collection Site will have within its binder copies of all FDA and EUA approvals. Please contact email@example.com for copies of certifications. Certifications will be included at each site.